Valuation: Galectin Therapeutics Inc.

Market Cap 294M 266M 246M 222M 419M 27.43B 435M 2.97B 1.17B 14.8B 1.1B 1.08B 46.76B P/E 2026 *
-11.2x
P/E 2027 * -18.2x
Enterprise Value 294M 266M 246M 222M 419M 27.43B 435M 2.97B 1.17B 14.8B 1.1B 1.08B 46.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
46.56%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Galectin Therapeutics Inc.

1 day-3.64%
1 week-13.91%
Current month-12.35%
1 month-19.61%
3 months-17.09%
6 months+34.10%
Current year-30.05%
1 week 2.82
Extreme 2.82
3.53
1 month 2.82
Extreme 2.82
3.73
Current year 2.02
Extreme 2.025
5.55
1 year 2.02
Extreme 2.025
7.13
3 years 0.73
Extreme 0.726041
7.13
5 years 0.73
Extreme 0.726041
7.13
10 years 0.73
Extreme 0.726041
9.49
Manager TitleAgeSince
Chief Executive Officer 56 01/09/2020
Director of Finance/CFO 58 30/06/2013
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 83 11/02/2009
Director/Board Member 65 30/04/2011
Director/Board Member 77 30/11/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Exercice

Chairman

34,376,167 34.0866%
14/07/26 Exercice

Chief Technology Officer

48,750 0.0483%
29/06/26 Exercice

Director

66,804 0.1014%
Change 5-day change 1-year change 3-year change Capi.($)
-3.64%-13.91%-51.50%+48.47% 294M
+1.15%-2.81%+55.79%+71.12% 66.37B
+1.08%-1.35%+9.51%+91.61% 58.86B
+0.95%+0.90%+26.53%+87.46% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
+0.14%-1.49%+83.09%+58.02% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.66%-2.35%+26.72%+160.23% 40B
Weighted average by Cap. -0.08%-2.18%+35.09%+147.17%

Financials

2026 *2027 *
Net sales - -
Net income -20.9M -18.97M -17.53M -15.81M -29.85M -1.95B -30.99M -211M -83.53M -1.05B -78.41M -76.76M -3.33B -16.8M -15.25M -14.09M -12.71M -23.99M -1.57B -24.91M -170M -67.14M -847M -63.03M -61.7M -2.68B
Net Debt - -
Projected Income Statement - Annual - Galectin Therapeutics Inc.
Logo Galectin Therapeutics Inc.
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Employees
9
Date Price Change Volume
17/11/26 US$2.910 -3.64% 263,205
16/11/26 US$3.020 -0.98% 231,994
13/11/26 US$3.050 -2.87% 181,588
12/11/26 US$3.140 -4.56% 226,411
11/11/26 US$3.290 -2.66% 77,983
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.910USD
Average target price
11.00USD
Spread / Average Target
+278.01%
  1. Stock Market
  2. Stocks
  3. GALT Stock